In spite of continuous progresses in the treatment of early-stage BC during the last decades, BC recurrence, in the form of local or distant relapses, occurs in approximately 15–20% of patients with surgically-resected HR+/HER2− BC [113,114]. Here, HR is linked to breast cancer.